Please login to the form below
genomes
This page shows the latest genomes news and features for those working in and with pharma, biotech and healthcare.
Daily Brief: Brexit reshuffle brings new health minister, Celgene thalassemia success, Wellcome read to leap into future
The Leap Fund aims to foster breakthroughs on a par with dazzling innovations such as the cryro-electron microscopy, and nanopore genome sequencing, but aims to accelerate the rate at which
Latest news
-
Loxo, Bayer get quick FDA review for ‘precision’ cancer drug
Only latterly have TRK inhibitors such as larotrectinib entered clinical testing, aided by tumour genome sequencing that can be used to identify patients who may benefit from treatment with these precision
-
Daily Brief: Calls for early Brexit deal for science and innovation, Gottlieb threatens to name and shame
Genomics. Illumina buys genome data analysis firm. Genome sequencing leader Illumina has paid $100m for Edico Genome, a company which has developed software to speed-up the reading of genetic data. ... Our acquisition of Edico Genome is a big step toward
-
Lilly adds AurKa Pharma to oncology buying spree
Aurora kinases, consisting of Aurora A, Aurora B and Aurora C, are key mitotic regulators required for genome stability and are frequently overexpressed in cancerous tumours.
-
Roche digs out soil drug discovery deal with Lodo
Roche unit Genentech has signed an approximately $1bn alliance with Lodo Therapeutics that will delve into the genomes of microbes in soil in the hope of finding new drug therapies. ... Under the terms of the Genentech deal, Lodo will deploy its genome
-
Roche digs out soil drug discovery deal with Lodo
Roche unit Genentech has signed an approximately $1bn alliance with Lodo Therapeutics to delve into the genomes of microbes in soil in the hope of finding new drug therapies. ... Under the terms of the Genentech deal, Lodo will deploy its genome mining
More from news
Approximately 6 fully matching, plus 155 partially matching documents found.
Latest Intelligence
-
Can new data aggregators shift the balance of power away from pharma?
However, it was only 20 years ago that several genomics companies, led by Human Genome Sciences Inc, thought they could secure a monopoly position over unprecedented drug targets by filing patents ... on gene sequences emerging from their own human
-
30 Women Leaders in UK Healthcare
100, 000 Genomes Project. ... It represents the world’s largest depository of whole genomes with associated clinical data, and is already being used to diagnose and personalise treatment for people with rare diseases and cancers.
-
Integrating digital biomarkers into precision medicine
In many ways, this model parallels traditional biomarker development where, for example, blood samples can be collected early in clinical research to then support genome-wide association studies to detect genetic
-
Avoiding data pitfalls in clinical research
This is a deceptively difficult task, but once patient IDs are matched within the clinical trial database, researchers have access to an analytical environment that ties together the entire genome, adverse ... With the terabytes and petabytes of data
-
Reactivating drug research programmes
One research-led breakthrough to hit the headlines involves the use of genome sequencing to isolate different strains of tuberculosis (TB), allowing the disease to be diagnosed more quickly. ... Just a decade ago, it would have cost many millions of
More from intelligence
Approximately 1 fully matching, plus 24 partially matching documents found.
Latest appointments
-
Editas Medicine names James Mullen as chairman
Genome editing company Editas Medicine has appointed James Mullen as chairman of the board of directors.
-
Editas Medicine adds to its board of directors
Editas Medicine adds to its board of directors. Jessica Hopfield will also serve on the genome editing firm's audit committee. ... Genome editing company Editas Medicine has strengthened its board of directors with the addition of Jessica Hopfield, who
-
Former GSK CEO joins Synthego’s advisory board
I look forward to contributing to the company’s success as the business extends further into the genome engineering market.”. ... Andrew’s appointment strengthens the company’s position as a leader in genome engineering solutions.”.
-
Paul Stockdale joins Oxford BioDynamics as CFO
A spin-out from Oxford University, Oxford BioDynamics focuses on the discovery and development of epigenetic biomarkers based on regulatory genome architecture.
-
Intellia Therapeutics appoints Dr Moncef Slaoui and Dr Frank Verwiel
Genome editing group Intellia Therapeutics has appointed Moncef Slaoui and Frank Verwiel to join its board of directors at a time when the board is establishing a Science and Technology Committee, ... We look forward to their guidance as we continue to
More from appointments
Approximately 0 fully matching, plus 14 partially matching documents found.
Latest from PMHub
-
Medical information in precision medicine
As the cost of sequencing continues to drop, it will become feasible to sequence the entire human genome easily.
-
Big data, privacy and the rise of genomic testing
The cost of sequencing the entire human genome has dropped from $100M in 2001 to less than $1000 in 2014. ... The golden age of data. Experts predict up to 50 million genomes will be sequenced by 2022.
-
Marketing strategy in complex environments
genome. With personalised medicine, products with defined patient populations are becoming increasingly prevalent and are transforming certain therapy areas into finely segmented markets.
-
Precision medicine and the changing role of the healthcare professional
We are able to sequence a patient’ s genome for less than $1000, and the crucial problem is no longer being able to gather this kind of genetic and “-omics” data,
-
What pharma needs to know about genomic data in 2016
Since the Genome Project started in 1990, genetics has been the “ great hope” of healthcare, promising to solve the great mystery of how illness and disease affect us on an individual
More from PMHub
Approximately 1 fully matching, plus 11 partially matching documents found.
Featured jobs
-
Client Services Director - Med Comms
-
Great salary and bebefits
-
Senior Account Manager
-
Competitive salary commensurate with experience
- Business Unit Head, Medical Communications, London
-
Excellent package
- Account Director, Consumer Healthcare PR, Global PR agency
-
£50, 000 – £58, 000
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- Home based, Editorial Team Leader, Medical Communications
-
Excellent package
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
-
Account Manager
-
£40, 000 - £45, 000 benefits
- Home based, Chief Medical Writer, Medical Communications
-
Excellent package
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Home based, Principal Medical Writer, Medical Communications
-
Excellent package
Subscribe to our email news alerts
- Communiqué Awards 2018: Photo Gallery - Communiqué Awards 2016
- GSK sells eczema and psoriasis drug to Dermavant for £250m
- Moving annual total (MAT)
- MaxCyte gets green light for solid tumour cell therapy
- Brexit rebels win vote on European Medicines Agency alignment
- Positive mid-stage trial gives Allergy’s investors some welcome relief
- Merck & Co joins big pharma pricing pledge – but sceptics unconvinced
- Aurora partners with PIPHealth and taps into patient panels
- FDA’s Gottlieb lambasts industry’s biosimilar-blocking tactics
- Allergan’s abicipar matches AMD blockbuster Lucentis in phase III
- OUTiCO growth in multi-channel creates more job openings
- Daily brief: Novartis spends big on ezcema, Kite invests, another gene therapy IPO
PMHub
Kantar Health
Kantar Health is a leading global healthcare consulting firm and trusted advisor to many of the world’s leading pharmaceutical, biotech,...
Latest intelligence
- Developing advocacy in the pharmaceutical industry.
- The importance of advocacy programmes...
- GDPR and events. What does the pharma industry need to know?
- Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
- Digital trends in B2B sales - how far behind is Pharma?
- The modern approach to B2B sales is data-driven, and enabled by digital tools....
Quick links
Infographics
